UroVysionTM testing can lead to early identification of intravesical therapy failure in patients with high risk non-muscle invasive bladder cancer

Jared M Whitson, Anna B. Berry, Peter R. Carroll, Badrinath R. Konety

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: In this study, we investigated the ability of UroVysionTM to assess response to intravesical therapy in patients with high risk superficial bladder tumors. Materials and Methods: We performed a retrospective review of patients undergoing intravesical therapy for high risk superficial bladder tumors. Urine specimens were collected for UroVysionTM analysis before and immediately after a course of intravesical therapy. Cytology and cystoscopy were performed six weeks after treatment, using either a positive cytology or visible abnormality on cystoscopy as a prompt for biopsy. The operating characteristics of the UroVysionTM test were then determined. Results: 41 patients were identified in whom 47 cycles of induction and 41 cycles of maintenance intravesical therapy were given during the study period. This yielded a total of 88 treatment and evaluation cycles. Median follow-up was 9 months per induction (range 1-21 months) and 13 months per patient (range 1-25 months). A total of 133 urine samples were collected for UroVysionTM of which 40 were positive. Based upon standard clinical evaluation, 41 biopsies were performed which detected 20 recurrences. UroVysionTM testing performed immediately upon completion of therapy for the 41 patients undergoing biopsy yielded a sensitivity, specificity, and accuracy of 85%, 61%, and 71%. Conclusions: The use of UroVysionTM following intravesical therapy for high-risk superficial bladder tumors helps to identify patients at high risk of refractory or recurrent disease who should undergo immediate biopsy under anesthesia.

Original languageEnglish (US)
Pages (from-to)664-670
Number of pages7
JournalInternational Braz J Urol
Volume35
Issue number6
DOIs
StatePublished - Nov 2009
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Biopsy
Cystoscopy
Therapeutics
Cell Biology
Urine
Anesthesia
Maintenance
Recurrence
Sensitivity and Specificity

Keywords

  • BCG
  • Bladder neoplasms
  • Chemotherapy
  • Follow-up
  • Interferons
  • Superficial

ASJC Scopus subject areas

  • Urology
  • Medicine(all)

Cite this

UroVysionTM testing can lead to early identification of intravesical therapy failure in patients with high risk non-muscle invasive bladder cancer. / Whitson, Jared M; Berry, Anna B.; Carroll, Peter R.; Konety, Badrinath R.

In: International Braz J Urol, Vol. 35, No. 6, 11.2009, p. 664-670.

Research output: Contribution to journalArticle

Whitson, Jared M ; Berry, Anna B. ; Carroll, Peter R. ; Konety, Badrinath R. / UroVysionTM testing can lead to early identification of intravesical therapy failure in patients with high risk non-muscle invasive bladder cancer. In: International Braz J Urol. 2009 ; Vol. 35, No. 6. pp. 664-670.
@article{05e6358834774aa8a96339bd961ac947,
title = "UroVysionTM testing can lead to early identification of intravesical therapy failure in patients with high risk non-muscle invasive bladder cancer",
abstract = "Purpose: In this study, we investigated the ability of UroVysionTM to assess response to intravesical therapy in patients with high risk superficial bladder tumors. Materials and Methods: We performed a retrospective review of patients undergoing intravesical therapy for high risk superficial bladder tumors. Urine specimens were collected for UroVysionTM analysis before and immediately after a course of intravesical therapy. Cytology and cystoscopy were performed six weeks after treatment, using either a positive cytology or visible abnormality on cystoscopy as a prompt for biopsy. The operating characteristics of the UroVysionTM test were then determined. Results: 41 patients were identified in whom 47 cycles of induction and 41 cycles of maintenance intravesical therapy were given during the study period. This yielded a total of 88 treatment and evaluation cycles. Median follow-up was 9 months per induction (range 1-21 months) and 13 months per patient (range 1-25 months). A total of 133 urine samples were collected for UroVysionTM of which 40 were positive. Based upon standard clinical evaluation, 41 biopsies were performed which detected 20 recurrences. UroVysionTM testing performed immediately upon completion of therapy for the 41 patients undergoing biopsy yielded a sensitivity, specificity, and accuracy of 85{\%}, 61{\%}, and 71{\%}. Conclusions: The use of UroVysionTM following intravesical therapy for high-risk superficial bladder tumors helps to identify patients at high risk of refractory or recurrent disease who should undergo immediate biopsy under anesthesia.",
keywords = "BCG, Bladder neoplasms, Chemotherapy, Follow-up, Interferons, Superficial",
author = "Whitson, {Jared M} and Berry, {Anna B.} and Carroll, {Peter R.} and Konety, {Badrinath R.}",
year = "2009",
month = "11",
doi = "10.1590/S1677-55382009000600005",
language = "English (US)",
volume = "35",
pages = "664--670",
journal = "International braz j urol : official journal of the Brazilian Society of Urology",
issn = "1677-5538",
publisher = "Brazilian Society of Urology",
number = "6",

}

TY - JOUR

T1 - UroVysionTM testing can lead to early identification of intravesical therapy failure in patients with high risk non-muscle invasive bladder cancer

AU - Whitson, Jared M

AU - Berry, Anna B.

AU - Carroll, Peter R.

AU - Konety, Badrinath R.

PY - 2009/11

Y1 - 2009/11

N2 - Purpose: In this study, we investigated the ability of UroVysionTM to assess response to intravesical therapy in patients with high risk superficial bladder tumors. Materials and Methods: We performed a retrospective review of patients undergoing intravesical therapy for high risk superficial bladder tumors. Urine specimens were collected for UroVysionTM analysis before and immediately after a course of intravesical therapy. Cytology and cystoscopy were performed six weeks after treatment, using either a positive cytology or visible abnormality on cystoscopy as a prompt for biopsy. The operating characteristics of the UroVysionTM test were then determined. Results: 41 patients were identified in whom 47 cycles of induction and 41 cycles of maintenance intravesical therapy were given during the study period. This yielded a total of 88 treatment and evaluation cycles. Median follow-up was 9 months per induction (range 1-21 months) and 13 months per patient (range 1-25 months). A total of 133 urine samples were collected for UroVysionTM of which 40 were positive. Based upon standard clinical evaluation, 41 biopsies were performed which detected 20 recurrences. UroVysionTM testing performed immediately upon completion of therapy for the 41 patients undergoing biopsy yielded a sensitivity, specificity, and accuracy of 85%, 61%, and 71%. Conclusions: The use of UroVysionTM following intravesical therapy for high-risk superficial bladder tumors helps to identify patients at high risk of refractory or recurrent disease who should undergo immediate biopsy under anesthesia.

AB - Purpose: In this study, we investigated the ability of UroVysionTM to assess response to intravesical therapy in patients with high risk superficial bladder tumors. Materials and Methods: We performed a retrospective review of patients undergoing intravesical therapy for high risk superficial bladder tumors. Urine specimens were collected for UroVysionTM analysis before and immediately after a course of intravesical therapy. Cytology and cystoscopy were performed six weeks after treatment, using either a positive cytology or visible abnormality on cystoscopy as a prompt for biopsy. The operating characteristics of the UroVysionTM test were then determined. Results: 41 patients were identified in whom 47 cycles of induction and 41 cycles of maintenance intravesical therapy were given during the study period. This yielded a total of 88 treatment and evaluation cycles. Median follow-up was 9 months per induction (range 1-21 months) and 13 months per patient (range 1-25 months). A total of 133 urine samples were collected for UroVysionTM of which 40 were positive. Based upon standard clinical evaluation, 41 biopsies were performed which detected 20 recurrences. UroVysionTM testing performed immediately upon completion of therapy for the 41 patients undergoing biopsy yielded a sensitivity, specificity, and accuracy of 85%, 61%, and 71%. Conclusions: The use of UroVysionTM following intravesical therapy for high-risk superficial bladder tumors helps to identify patients at high risk of refractory or recurrent disease who should undergo immediate biopsy under anesthesia.

KW - BCG

KW - Bladder neoplasms

KW - Chemotherapy

KW - Follow-up

KW - Interferons

KW - Superficial

UR - http://www.scopus.com/inward/record.url?scp=77949495157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949495157&partnerID=8YFLogxK

U2 - 10.1590/S1677-55382009000600005

DO - 10.1590/S1677-55382009000600005

M3 - Article

C2 - 20028572

AN - SCOPUS:77949495157

VL - 35

SP - 664

EP - 670

JO - International braz j urol : official journal of the Brazilian Society of Urology

JF - International braz j urol : official journal of the Brazilian Society of Urology

SN - 1677-5538

IS - 6

ER -